5FNQ

Structure of the Keap1 Kelch domain in complex with a small molecule inhibitor.

Summary for 5FNQ

• Entry DOI: 10.2210/pdb5fnq/pdb
• Related: 5FNR 5FNS 5FNT 5FNU
• Descriptor: KELCH-LIKE ECH-ASSOCIATED PROTEIN 1, 3-(4-CHLOROPHENYL)PROPANOIC ACID (3 entities in total)
• Functional Keywords: transcription, keap1, nrf2, oxidative stress
• Biological source: MUS MUSCULUS (HOUSE MOUSE)
• Cellular location: Cytoplasm : Q9Z2X8
• Total number of polymer chains: 1
• Total formula weight: 33546.92

Authors

Davies, T.G.,Wixted, W.E.,Coyle, J.E.,Griffiths-Jones, C.,Hearn, K.,McMenamin, R.,Norton, D.,Rich, S.J.,Richardson, C.,Saxty, G.,Willems, H.M.G.,Woolford, A.J.,Cottom, J.E.,Kou, J.,Yonchuk, J.G.,Feldser, H.G.,Sanchez, Y.,Foley, J.P.,Bolognese, B.J.,Logan, G.,Podolin, P.L.,Yan, H.,Callahan, J.F.,Heightman, T.D.,Kerns, J.K. (deposition date: 2015-11-16, release date: 2016-04-13, Last modification date: 2024-01-10)

Primary citation

Davies, T.G.,Wixted, W.E.,Coyle, J.E.,Griffiths-Jones, C.,Hearn, K.,Mcmenamin, R.L.,Norton, D.,Rich, S.J.,Richardson, C.,Saxty, G.,Willems, H.M.G.,Woolford, A.J.,Cottom, J.E.,Kou, J.,Yonchuk, J.G.,Feldser, H.G.,Sanchez, Y.,Foley, J.P.,Bolognese, B.J.,Logan, G.A.,Podolin, P.L.,Yan, H.,Callahan, J.F.,Heightman, T.D.,Kerns, J.K.
Mono-Acidic Inhibitors of the Kelch-Like Ech-Associated Protein 1 : Nuclear Factor Erythroid 2-Related Factor 2 (Keap1:Nrf2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
J.Med.Chem., 59:3991-, 2016

PubMed Abstract: KEAP1 is the key regulator of the NRF2-mediated cytoprotective response, and increasingly recognized as a target for diseases involving oxidative stress. Pharmacological intervention has focused on molecules that decrease NRF2-ubiquitination through covalent modification of KEAP1 cysteine residues, but such electrophilic compounds lack selectivity and may be associated with off-target toxicity. We report here the first use of a fragment-based approach to directly target the KEAP1 Kelch-NRF2 interaction. X-ray crystallographic screening identified three distinct "hot-spots" for fragment binding within the NRF2 binding pocket of KEAP1, allowing progression of a weak fragment hit to molecules with nanomolar affinity for KEAP1 while maintaining drug-like properties. This work resulted in a promising lead compound which exhibits tight and selective binding to KEAP1, and activates the NRF2 antioxidant response in cellular and in vivo models, thereby providing a high quality chemical probe to explore the therapeutic potential of disrupting the KEAP1-NRF2 interaction.

PubMed: 27031670
DOI: 10.1021/ACS.JMEDCHEM.6B00228

Experimental method

X-RAY DIFFRACTION (1.91 Å)